142 related articles for article (PubMed ID: 19836653)
61. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases.
Schellekens AF; Mulder SF; van Eijndhoven PF; Smilde TJ; van Herpen CM
Gen Hosp Psychiatry; 2011; 33(1):83.e1-3. PubMed ID: 21353137
[No Abstract] [Full Text] [Related]
62. Yellowish nail pigmentation caused by sunitinib.
Espinosa Lara P; Bueno C; Aranegui B; Vargas-Machuca I; Jiménez Reyes J
Int J Dermatol; 2016 Aug; 55(8):e462-3. PubMed ID: 26971887
[No Abstract] [Full Text] [Related]
63. PISCES trial: the end does not always justify the means.
Barni S; Petrelli F
J Clin Oncol; 2014 Nov; 32(33):3782-3. PubMed ID: 25267749
[No Abstract] [Full Text] [Related]
64. Kidney cancer: sunitinib has similar efficacy irrespective of age in mRCC.
Killock D
Nat Rev Clin Oncol; 2014 Mar; 11(3):122. PubMed ID: 24492835
[No Abstract] [Full Text] [Related]
65. Kidney cancer: Sunitinib has similar efficacy irrespective of age in mRCC.
Killock D
Nat Rev Urol; 2014 Mar; 11(3):128. PubMed ID: 24492434
[No Abstract] [Full Text] [Related]
66. Scrotal cutaneous toxicity: an uncommon but important side-effect of sunitinib.
Gupta V; Rao A; Gupta S
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):132-3. PubMed ID: 25060046
[No Abstract] [Full Text] [Related]
67. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
68. Reply to S. Barni et Al and M. Sun et Al.
Garnick MB
J Clin Oncol; 2014 Nov; 32(33):3785. PubMed ID: 25267752
[No Abstract] [Full Text] [Related]
69. Reply to S. Barni et Al and M. Sun et Al.
Escudier B; Porta C; Powles T; Eisen T; Sternberg CN; Mehmud F; Cella D
J Clin Oncol; 2014 Nov; 32(33):3783-4. PubMed ID: 25267750
[No Abstract] [Full Text] [Related]
70. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?
Garnick MB
J Clin Oncol; 2014 May; 32(14):1392-3. PubMed ID: 24687838
[No Abstract] [Full Text] [Related]
71. "Hand foot genital syndrome": Proposition of a new term, induced by Sunitinib in a patient of metastatic renal cell carcinoma.
Ganjoo A; Ganjoo S; Das A
Dermatol Ther; 2021 Mar; 34(2):e14785. PubMed ID: 33480072
[No Abstract] [Full Text] [Related]
72. Kidney cancer: in crossover study, patients and physicians prefer pazopanib.
Phillips R
Nat Rev Urol; 2014 May; 11(5):246. PubMed ID: 24731995
[No Abstract] [Full Text] [Related]
73. A CT scan aspect of "hypodense thyroid gland" after sunitinib treatment for metastatic carcinoma of the kidney.
Vélayoudom-Céphise FL; Vian E; Bosewa T; Nallet E; Wemeau JL; Donnet JP
J Clin Endocrinol Metab; 2011 Mar; 96(3):590-1. PubMed ID: 21378222
[No Abstract] [Full Text] [Related]
74. Recall pneumonitis during systemic treatment with sunitinib.
Seidel C; Janssen S; Karstens JH; Welte T; Morgan M; Ganser A; Grünwald V
Ann Oncol; 2010 Oct; 21(10):2119-2120. PubMed ID: 20720089
[No Abstract] [Full Text] [Related]
75. Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.
Da Silva F; Thomas-Schoemann A; Huillard O; Goldwasser F; Blanchet B
Ann Oncol; 2016 Aug; 27(8):1651-2. PubMed ID: 27117534
[No Abstract] [Full Text] [Related]
76. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Hartmann JT; Kanz L
Arch Dermatol; 2008 Nov; 144(11):1525-6. PubMed ID: 19015436
[No Abstract] [Full Text] [Related]
77. Three cases of severe ulcerative esophagitis induced by SUTENT®.
Jeanniard-Malet O; Gravis G; Caillol F; Pesenti C; Bories E; Giovannini M
J Gastrointest Cancer; 2012 Mar; 43(1):128-30. PubMed ID: 20640604
[TBL] [Abstract][Full Text] [Related]
78. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
Kelly PJ; Weiss SE; Sher DJ; Perez-Atayde AR; Dal Cin P; Choueiri TK
J Clin Oncol; 2010 Sep; 28(25):e433-5. PubMed ID: 20547999
[No Abstract] [Full Text] [Related]
79. Images in clinical medicine. Sunitinib-associated hair depigmentation.
Brzezniak C; Szabo E
N Engl J Med; 2014 Apr; 370(17):e27. PubMed ID: 24758639
[No Abstract] [Full Text] [Related]
80. Sunitinib induced pyoderma gangrenosum-like ulcerations.
Akanay-Diesel S; Hoff NP; Kürle S; Haes J; Erhardt A; Häussinger D; Schulte KW; Bölke E; Matuschek C; Budach W; Gerber PA; Homey B
Eur J Med Res; 2011 Nov; 16(11):491-4. PubMed ID: 22027642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
